LGVN - Longeveron Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Miami,
United States
Type: Equity
LGVN price evolution
LGVN
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.38 | $0.22 | $0.18 | $0.11 |
| Inventory | ||||
| Total current assets | $23.77 | $13.41 | $3.76 | $5.85 |
| Long term investments | ||||
| Property, plant & equipment | $3.59 | $3.43 | $3.49 | $3.75 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $29.91 | $19.39 | $9.7 | $12.08 |
| Current liabilities | ||||
| Accounts payable | $0.89 | $0.6 | $1.47 | $0.64 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.1 | $3.21 | $5.29 | $3.89 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.28 | $4.48 | $6.66 | $5.34 |
| Shareholders' equity | ||||
| Retained earnings | -$105.53 | -$100.96 | -$89.04 | -$84.98 |
| Other shareholder equity | -$0 | -$0 | $0 | -$0.1 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.82 | |||
| Short term investments | ||||
| Net receivables | $0.11 | $0.22 | $0.06 | $0.42 |
| Inventory | ||||
| Total current assets | $5.85 | $20.28 | $35.38 | $1.85 |
| Long term investments | ||||
| Property, plant & equipment | $3.75 | $4.48 | $4.88 | $3.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $7.39 | |||
| Total investments | ||||
| Total assets | $12.08 | $27.41 | $42.77 | $9.24 |
| Current liabilities | ||||
| Accounts payable | $0.64 | $1.75 | $0.65 | $1.59 |
| Deferred revenue | $0.01 | |||
| Short long term debt | ||||
| Total current liabilities | $3.89 | $4.87 | $2.71 | $3.83 |
| Long term debt | $0.31 | |||
| Total noncurrent liabilities | $3.45 | |||
| Total debt | ||||
| Total liabilities | $5.34 | $6.91 | $5.31 | $7.28 |
| Shareholders' equity | ||||
| Retained earnings | -$84.98 | -$62.77 | -$43.94 | |
| Other shareholder equity | -$0.1 | -$0.46 | -$0.1 | $1.96 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.77 | $0.47 | $0.55 | $0.06 |
| Cost of revenue | ||||
| Gross Profit | $0.68 | $0.34 | $0.33 | -$0 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $5.33 | $3.84 | $4.42 | $5.44 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$4.57 | -$11.91 | -$4.06 | -$6.83 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.71 | $1.22 | $1.31 | $5.63 |
| Cost of revenue | ||||
| Gross Profit | $0.22 | $0.5 | $0.59 | $1.83 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $21.25 | $18.54 | $18.04 | $6.41 |
| Operating income | -$3.78 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.2 | $0.01 | ||
| Net income | ||||
| Net income | -$22.21 | -$18.84 | -$17.05 | -$3.72 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.52 | -$0.04 | $0.01 | $8.19 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $28.84 | $15.12 | $0.06 | $5.26 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $17.83 | $7.43 | -$3.01 | -$5.55 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$3.72 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$2.36 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $8.19 | -$0.68 | -$10.7 | -$0.26 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.26 | -$0.51 | $45.17 | $1.58 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.55 | -$15.15 | $24.83 | -$1.05 |
News
Fundamentals
| Market cap | $12.37M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 14.84M |
| Revenue | $1.85M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$27.37M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.45 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.68 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.84 |
|---|---|
| ROA | -154.01% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.67 |
| Quick ratio | N/A |